Free Trial
NASDAQ:GRCE

Grace Therapeutics (GRCE) Stock Price, News & Analysis

Grace Therapeutics logo
$1.76 -0.06 (-3.04%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Grace Therapeutics Stock (NASDAQ:GRCE)

Advanced

Key Stats

Today's Range
$1.75
▼
$1.83
50-Day Range
$1.78
▼
$2.29
52-Week Range
$1.67
▼
$5.18
Volume
26,143 shs
Average Volume
342,829 shs
Market Capitalization
$36.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders.

The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments.

Grace Therapeutics was formerly known as Acasti Pharma and adopted its current name as it focused on the development programs associated with Grace Therapeutics. The company’s candidates remain investigational and are not approved medicines.

AI Generated. May Contain Errors.

Grace Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

GRCE MarketRank™: 
1.96831079289 of 5 stars

Grace Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 687th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Grace Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Grace Therapeutics has a consensus price target of $6.00, representing about 241.9% upside from its current price of $1.76.

  • Amount of Analyst Coverage

    Grace Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Grace Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Grace Therapeutics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Grace Therapeutics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Grace Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.89% of the float of Grace Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Grace Therapeutics has a short interest ratio ("days to cover") of 12.33, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Grace Therapeutics has recently decreased by 0.95%, indicating that investor sentiment is improving.
  • Dividend Yield

    Grace Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Grace Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Grace Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Grace Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for GRCE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Grace Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.84% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    6.08% of the stock of Grace Therapeutics is held by institutions.

  • Read more about Grace Therapeutics' insider trading history.
Receive GRCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grace Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GRCE Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Grace: Fiscal Q2 earnings snapshot
Grace Therapeutics (GRCE) Expected to Release Earnings on Thursday
See More Headlines

GRCE Stock Analysis - Frequently Asked Questions

Grace Therapeutics' stock was trading at $3.46 on January 1st, 2026. Since then, GRCE shares have decreased by 49.3% and is now trading at $1.7550.

Grace Therapeutics, Inc. (NASDAQ:GRCE) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04.

Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/16/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:GRCE
Previous Symbol
NASDAQ:GRCE
CIK
1444192
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.00
Potential Upside/Downside
+241.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-37.00%
Return on Assets
-35.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.61
Quick Ratio
13.61

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.99 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
21,036,000
Free Float
18,756,000
Market Cap
$36.92 million
Optionable
Optionable
Beta
0.43
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:GRCE) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners